Durvalumab Combo Misses OS Endpoint in Frontline Metastatic NSCLC
The frontline combination of durvalumab (Imfinzi) and tremelimumab did not induce a statistically significant improvement in overall survival compared to standard chemotherapy in patients with metastatic non–small cell lung cancer.
Source: OncLive